小剂量米非司酮治疗子宫肌瘤的效果观察及不良反应发生率影响分析
|
摘要
目的探讨对子宫肌瘤患者选择小剂量米非司酮药物治疗后获得的临床效果以及对不良反应发生率产生的影响。方法选择本院2016年7月至2018年2月收治的182例子宫肌瘤患者作为实验对象;数字奇偶法分组后明确各组用药措施;对照组(91例):选择达那唑药物完成治疗;观察组(91例):选择达那唑+小剂量米非司酮药物完成治疗;对比治疗效果。结果治疗前,两组患者在症状表现方面,差异无统计学意义;治疗后,观察组阴道出血、白带异常以及腹部肿块发生率明显低于对照组,差异有统计学意义(P<0.05);治疗前,两组患者在子宫肌瘤体积以及血红蛋白水平表现方面,差异无统计学意义;治疗后,观察组子宫肌瘤体积明显小于对照组,血红蛋白水平明显高于对照组,差异有统计学意义(P<0.05);观察组子宫肌瘤患者总不良反应发生率与对照组比较,差异无统计学意义。结论子宫肌瘤患者在接受治疗期间,小剂量米非司酮药物的有效应用,对于患者症状改善、子宫肌瘤体积缩小以及血红蛋白水平提升,效果显著,最终对于子宫肌瘤患者的康复加快,奠定基础。
Objective To investigate the clinical effects of small doses of mifepristone in patients with uterine fibroids and the impact on the incidence of adverse reactions. Methods A total of 182 patients with uterine fibroids admitted to our hospital from July 2016 to February 2018 were selected as experimental subjects. The digital parity method was used to determine the medications for each group. Control group(91 cases) : danazole was selected to complete the treatment. Observation group(91 cases) : danazole + small dose of mifepristone was selected to complete the treatment;Compare the therapeutic effects. Results Before treatment, there was no significant difference in symptom performance between the two groups. After treatment, the incidence of vaginal bleeding, vaginal discharge and abdominal mass in the observation group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05); Before treatment, the difference between uterine fibroid volume and hemoglobin level was not significant. After treatment, the volume of uterine fibroids in the observation group was significantly smaller than that in the control group, and the hemoglobin level was significantly higher than that in the control group. The difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group. Conclusion The effective application of low-dose mifepristone in patients with uterine fibroids has a significant effect on the improvement of symptoms, the reduction of uterine fibroids and the increase of hemoglobin level, and the recovery of patients with uterine fibroids is accelerated. Lay the foundation.
Objective To investigate the clinical effects of small doses of mifepristone in patients with uterine fibroids and the impact on the incidence of adverse reactions. Methods A total of 182 patients with uterine fibroids admitted to our hospital from July 2016 to February 2018 were selected as experimental subjects. The digital parity method was used to determine the medications for each group. Control group(91 cases) : danazole was selected to complete the treatment. Observation group(91 cases) : danazole + small dose of mifepristone was selected to complete the treatment;Compare the therapeutic effects. Results Before treatment, there was no significant difference in symptom performance between the two groups. After treatment, the incidence of vaginal bleeding, vaginal discharge and abdominal mass in the observation group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05); Before treatment, the difference between uterine fibroid volume and hemoglobin level was not significant. After treatment, the volume of uterine fibroids in the observation group was significantly smaller than that in the control group, and the hemoglobin level was significantly higher than that in the control group. The difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group. Conclusion The effective application of low-dose mifepristone in patients with uterine fibroids has a significant effect on the improvement of symptoms, the reduction of uterine fibroids and the increase of hemoglobin level, and the recovery of patients with uterine fibroids is accelerated. Lay the foundation.
引文
[1]张立新,乔菲,袁丽.桂枝茯苓汤联合米非司酮治疗子宫肌瘤疗效观察[J].世界中西医结合杂志,2018,13(9):1259-1262.
[2]张生兰,马西文.宫瘤消胶囊联合米非司酮治疗子宫肌瘤对患者子宫肌瘤体积及激素水平的影响[J].世界中医药,2018,13(11):2749-2752.
[3]李丽.桂枝茯苓加减丸联合米非司酮治疗子宫肌瘤的临床效果观察[J].按摩与康复医学,2018,9(22):28-29.
[4]李松芳.小剂量米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤的临床疗效[J].北方药学,2018,15(11):28-29.
[5]李玉红.小剂量米非司酮联合孕三烯酮治疗围绝经期子宫肌瘤的效果分析[J].河南医学研究,2018,27(19):3569-3570.
[6]文丽芳,丁洁.米非司酮与宫瘤消胶囊联合治疗子宫肌瘤效果观察[J].慢性病学杂志,2018,19(10):1439-1441.
[7]楼青青,周晓明.宫瘤宁联合米非司酮对子宫肌瘤患者血清表皮生长因子、基质金属蛋白酶9及血管生成素-2水平的影响[J].中国妇幼保健,2018,33(19):4408-4410.
[8]赵正滢.中药消瘤汤配伍米非司酮对子宫肌瘤患者子宫肌瘤及肌瘤体积及激素指标水平的影响[J].现代医用影像学,2018,27(5):1771-1772.
[2]张生兰,马西文.宫瘤消胶囊联合米非司酮治疗子宫肌瘤对患者子宫肌瘤体积及激素水平的影响[J].世界中医药,2018,13(11):2749-2752.
[3]李丽.桂枝茯苓加减丸联合米非司酮治疗子宫肌瘤的临床效果观察[J].按摩与康复医学,2018,9(22):28-29.
[4]李松芳.小剂量米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤的临床疗效[J].北方药学,2018,15(11):28-29.
[5]李玉红.小剂量米非司酮联合孕三烯酮治疗围绝经期子宫肌瘤的效果分析[J].河南医学研究,2018,27(19):3569-3570.
[6]文丽芳,丁洁.米非司酮与宫瘤消胶囊联合治疗子宫肌瘤效果观察[J].慢性病学杂志,2018,19(10):1439-1441.
[7]楼青青,周晓明.宫瘤宁联合米非司酮对子宫肌瘤患者血清表皮生长因子、基质金属蛋白酶9及血管生成素-2水平的影响[J].中国妇幼保健,2018,33(19):4408-4410.
[8]赵正滢.中药消瘤汤配伍米非司酮对子宫肌瘤患者子宫肌瘤及肌瘤体积及激素指标水平的影响[J].现代医用影像学,2018,27(5):1771-1772.